SCHEMBL6923780

SCHEMBL6923780

CC(=O)NCCc1c[nH]c2ccc(OCc3ccccc3)cc12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 6/20 0.82
MTNR1B P49286 6/20 0.82
TRPM8 Q7Z2W7 3/20 0.78
LTA4H P09960 5/20 0.74
PLA2G2A P14555 5/20 0.74
KDM4E B2RXH2 3/20 0.70
ALDH1A1 P00352 2/20 0.70
CYP1A2 P05177 2/20 0.70
CYP3A4 P08684 2/20 0.70
CYP2D6 P10635 2/20 0.70
HPGD P15428 2/20 0.70
BLM P54132 2/20 0.70
NOTUM Q6P988 2/20 0.70
MEN1 O00255 1/20 0.70
CYP1A1 P04798 1/20 0.70
MPO P05164 1/20 0.70
HTR1A P08908 1/20 0.70
NQO2 P16083 1/20 0.70
HTR2B P41595 1/20 0.70
RAB9A P51151 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18239800 0.90 MTNR1A (1.00) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL17040352 0.89 SIRT2 (0.78) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL18222539 0.89 TRPM8 (0.75) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL7723651 0.89 TRPM8 (0.78) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL7731853 0.89 TRPM8 (0.77) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL18239801 0.88 MTNR1A (0.94) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL17037429 0.87 SIRT2 (0.74) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL8206907 0.86 TRPM8 (0.73) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL9121394 0.85 MTNR1A (0.71) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A
SCHEMBL4573946 0.85 TRPM8 (0.69) MTNR1AMTNR1BTRPM8LTA4HPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025099444-A1 N-Acetylserotonin (NAS) Analogues Beckley Psytech Limited (GB) 2025-05-15 WO disclosed
US-20220390454-A1 BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION ARTEREZ, INC. (US) 2022-12-08 US disclosed
WO-2021062298-A1 BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION ARTEREZ, INC. (US) 2021-04-01 WO disclosed
WO-2004085392-A1 MELATONIN DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL DYSFUNCTIONS FAUST PHARMACEUTICALS (FR) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220390454-A1 BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION SDCBP, LGALS2, SDC1 MTNR1A 3988/4885MTNR1B 3697/4885TRPM8 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.